Eli Lilly up as Novo Nordisk's obesity drug underperforms in Copenhagen trial

Shares of U.S. drugmaker Eli Lilly LLY.N rise 4.3% to $1,053 in premarket trading

Danish drugmaker Novo Nordisk NOVOb.CO says its experimental obesity drug, CagriSema, did not meet the primary endpoint in a trial designed to show it was non-inferior to competitor Eli Lilly’s Tirzepatide in reducing body weight

Novo says it plans to begin a higher-dose trial of CagriSema in H2 2026 with U.S. FDA decision expected by late 2026

Novo says CagriSema achieved a 23% reduction in body weight over 84 weeks, compared to 25.5% for Eli Lilly's tirzepatide in the trial

U.S.-listed shares of Novo Nordisk fall 8.2% to $43.53 premarket

In 2025, Lilly down 6.1% while Novo down 7.7%